Compass Therapeutics, Inc. (CMPX) Tops Q3 EPS by 3c

Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q3 EPS of ($0.08), $0.03 better than the analyst estimate of ($0.11).

For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Geovax Labs receives Nasdaq non-compliance notice over equity rule
• Artisan Partners reports $183.4B in AUM as of June 2026